Given that today’s medical challenges are far more complex than before, our member companies believe in connecting their own expertise and capabilities with those of HCPs and HCOs.
Connections between industry, HCPs and HCOs benefit all three and, most importantly, patients. This collaborative work has a profound and positive influence on the quality of patient treatment and the value of future research. In fact, our joint research and co-operation has not only helped develop life-saving medicines but also led to advancements in patient care and medical science.
We believe that we have a duty to provide HCPs and HCOs with the latest information on our medicines to help them to make the best treatment recommendations to their patients. HCPs wish to stay informed about current and new medicines to provide patients with the best treatments and choice. In turn, they provide us with information on how to improve our medicines through ongoing feedback on how the medicines work in clinical settings.
In 2013, the European Federation of Pharmaceutical Industries and Associations’ (EFPIA) adopted a Disclosure Code regarding Transfers of Value to HCPs and HCOs for implementation in 2016. IPHA, as a member of EFPIA, changed its Code of Practice to reflect this additional transparency. Under this revised IPHA code, summary details of how IPHA member companies engage with and support HCPs and HCOs through direct or indirect financial support, or ‘Transfers of Value’, have been made public on www.transferofvalue.ie since 1st July 2016.